You are right and have been pointing it out for some time. As per past presentations - lower dosage ineffective and they reduced higher dosage value - does it mean they are running the trials at sub-optimal levels to eliminate adverse events?
We did at one point see a presentation that showed that the AD P2b/3 trial would be using 30mg and 50mg. Unfortunately I did not save that presentation.
Now all presentations also for PDD and Rett mask the high and low dose with a footnote stating that it is due to complete blinding of the trial.
Btw. did you not make a calculation from mouse doses that clarified why PDD is only 10mg and 20mg?
All presentations to date has stated no safety issues, including from the original P2 part A trial in AD using 30mg and 50mg - was Anavex and trial investigator lying about AEs?
Market Data 
Markets 
AI
